Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct) a randomised, double-blind, placebo-controlled phase 3 trial /

Trøseid Marius, Arribas José R, Assoumou Lambert, Holten Aleksander Rygh, Poissy Julien, Terzić Vida, Mazzaferri Fulvia, Baño Jesús Rodríguez, Eustace Joe, Hites Maya, Joannidis Michael, Paiva José-Artur, Reuter Jean, Püntmann Isabel, Patrick-Brown Thale D J H, Westerheim Elin, Nezvalova-Henriksen Katerina, Beniguel Lydie, Dahl Tuva Børresdatter, Bouscambert Maude, Halanova Monika, Péterfi Zoltán, Tsiodras Sotirios, Rezek Michael, Briel Matthias, Ünal Serhat, Schlegel Martin, Ader Florence, Lacombe Karine, Amdal Cecilie Delphin, Kollaborációs szervezet: EU SolidAct study group, Hajdu Edit, et al
2023